Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART19-IL18-eDHFR in Relapsed or Refractory Follicular Lymphoma
NCT07343934Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART19-IL18-eDHFR in follicular lymphoma (FL) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Change in Tumor Uptake on [18F]FP-TMP PET/CT at 6 months. Started May 2026; status: recruiting.
02
Drugs
huCART19-IL18-eDHFR
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07343934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343934.